The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, BRS, BPI and CRBP

NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

AVEO Pharmaceuticals, Inc. (AVEO)
Class Period: August 4, 2016 to January 31, 2019
Lead Plaintiff Deadline: April 26, 2019

The complaint alleges that during the class period AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

Get additional information about the AVEO lawsuit: http://www.kleinstocklaw.com/pslra-1/aveo-pharmaceuticals-inc-loss-submission-form?wire=3

Bristow Group Inc. (BRS)
Class Period: February 8, 2018 to February 12, 2019
Lead Plaintiff Deadline: April 15, 2019

The lawsuit alleges that throughout the class period, Bristow Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Bristow lacked adequate monitoring processes related to non-financial covenants within its secured financing and lease agreements; (2) Bristow could not reasonably assure compliance with certain non-financial covenants; (3) Bristow was reasonably likely to breach certain agreements; (4) Bristow had understated its short-term debt; (5) the required corrections would materially impact financial statements; (6) there was a material weakness in Bristow’s internal controls over financial reporting; and (7) as a result of the foregoing, defendants’ positive statements about Bristow’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the BRS lawsuit: http://www.kleinstocklaw.com/pslra-1/bristow-group-inc-loss-submission-form?wire=3

Bridgepoint Education Inc. (BPI)
Class Period: March 8, 2016 to March 7, 2019
Lead Plaintiff Deadline: May 10, 2019

The complaint alleges Bridgepoint Education Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Bridgepoint’s processes for recording revenue for its FTG program were inaccurate; (ii) Bridgepoint maintained deficient internal controls; (iii) due to the foregoing deficiencies, Bridgepoint was prone to and did commit material accounting errors related to revenue, provision for bad debts, accounts receivable and deferred revenue, which resulted in the overstatement of revenue and expenses; and (iv) as a result, Bridgepoint’s public statements were materially false and misleading at all relevant times.

Get additional information about the BPI lawsuit: http://www.kleinstocklaw.com/pslra-1/bridgepoint-education-inc-loss-submission-form?wire=3

Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Class Period: November 14, 2016 to February 28, 2019
Lead Plaintiff Deadline: May 13, 2019

During the class period, Corbus Pharmaceuticals Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Get additional information about the CRBP lawsuit: http://www.kleinstocklaw.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.